GET DAILY SIGNALSWhy Is Fulgent Genetics (FLGT) Stock Up +18.22% Today?
Key Takeaways
- FLGT shares surged roughly 18.22% in Thursday's session, jumping from a prior close of $18.66 to about $22.06.
- The primary catalyst was a much stronger-than-expected third-quarter 2026 earnings report released after Wednesday's close.
- Non-GAAP EPS of -$0.09 crushed the -$0.65 consensus, while revenue of $90.4 million beat the $86.3 million estimate.
- Improved billing and collection rates, plus higher full-year guidance, reinforced the bullish reaction.
- The move diverged sharply from broader market tone and reflected sector-specific, company-driven momentum.
- Traders are now watching whether the earnings-driven re-rating holds and how the company's AI pathology and therapeutic pipeline develop.
- For deeper insight, explore Price Targets, Earnings, and Forecast data on Fulgent Genetics.
- Discover how algorithmic strategies are positioning across the market on Tickeron's Trending AI Robots page.
Opening Summary
Fulgent Genetics, Inc. (FLGT), a technology-based genetic testing and laboratory services company that also operates a therapeutic development business, delivered one of the day's standout gains. The stock climbed approximately 18.22%, rising from a prior close of $18.66 to around $22.06 in intraday trading. The rally was driven squarely by a third-quarter earnings report that handily exceeded Wall Street expectations and featured an improved full-year outlook, triggering a sharp re-rating of a stock that had been heavily sold off in recent months.
Earnings Results: A Decisive Beat
The dominant catalyst was Fulgent's third-quarter 2026 financial results, released after Wednesday's closing bell. The company posted a non-GAAP net loss of just $0.09 per share, dramatically better than the $0.65-per-share loss analysts had projected. Revenue came in at $90.4 million, up roughly 8% year over year and ahead of the $86.3 million consensus. On a GAAP basis, the loss narrowed to $13.2 million, or $0.48 per share, a sharp sequential improvement from the $29.5 million loss recorded in the second quarter.
Margin Recovery and Billing Fix
Beyond the headline numbers, investors focused on the quality of the beat. Non-GAAP gross margin recovered to 36.3% from 31.3% in the prior quarter, as management made meaningful progress resolving a self-inflicted billing and revenue-cycle transition that had weighed on collections in recent periods. Better collection rates and a $3.2 million bad-debt recovery also helped narrow the non-GAAP operating loss. This signaled to the market that the margin pressure that drove the stock lower earlier in the year may be easing.
Improved Guidance
Management's updated outlook added fuel to the rally. Fulgent reaffirmed full-year 2026 revenue guidance of $330 million to $340 million but lifted its non-GAAP EPS outlook to a loss of $1.65 to $1.75 per share, up from the prior range of $2.22 to $2.35 per share. The company also raised its year-end cash forecast to approximately $630 million, supported by a $112.3 million federal tax refund, and ended the quarter with about $652.4 million in cash and marketable securities.
Market Context and Trading Activity
The surge in FLGT shares was largely company-specific, reflecting the earnings surprise rather than broad sector or index momentum. Trading volume was elevated relative to the stock's typical daily activity, consistent with strong conviction behind the earnings-driven move. The rally also marked a sharp reversal after a prolonged stretch of weakness, with the shares reclaiming levels last seen before the second-quarter guidance reduction and subsequent slide. The move pushed the stock well off recent lows and signaled renewed investor confidence in the company's margin trajectory.
What Comes Next for FLGT
Looking ahead, investors will monitor whether Fulgent can sustain its collection-rate recovery and continue integrating its Bako Diagnostics and StrataDx acquisitions. The company's AI-driven pathology platform remains a key growth narrative, with five additional AI applications planned for deployment in the fourth quarter. Its lead therapeutic candidate, FID-007, is advancing toward Phase 3 preparation, though the start of that trial is not yet firmly timed. Risks include the ongoing in-sourcing of testing by a major precision-diagnostics customer, remaining billing-system work, and regulatory considerations around reimbursement and the Clinical Lab Fee Schedule. The next earnings report will be the clearest test of whether this re-rating is durable.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-driven trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. Only the bots demonstrating the most robust recent results are featured in this section. Explore the page to see how algorithmic strategies are navigating today's fast-moving markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FLGT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for FLGT moved above the 200-day moving average on October 02, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +2.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where FLGT advanced for three days, in 188 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
FLGT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FLGT as a result. In 56 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for FLGT turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 37 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
FLGT moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for FLGT crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FLGT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for FLGT entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.513) is normal, around the industry mean (66.084). P/E Ratio (-6.594) is within average values for comparable stocks, (2.723). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.013) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. FLGT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FLGT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of genetic diagnostics services
Industry MedicalSpecialties
Advertisement